About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Nebulized Verapamil in COPD Exacerbations

NCT07866989·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Ain Shams University

Age

41–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age older than 40 years
Male or female
Diagnosis of acute exacerbation of chronic obstructive pulmonary disease according to GOLD 2023 criteria
With or without respiratory failure
Left ventricular ejection fraction greater than 55%
Right ventricular systolic pressure greater than 30 mmHg

You may not be if

Pre-existing cardiac disorders, including severe left ventricular dysfunction
Arrhythmias
Heart block
Hypotension
Bradycardia
Known hypersensitivity to verapamil
Requirement for mechanical ventilation
Interstitial lung disease
Bronchiectasis
Pneumonia
Pulmonary embolism
Lung cancer

The record

StatusCompleted

PhaseNo phase

Taking part60

StartedApr 2023

UpdatedOct 9, 2026

Conditions

Chronic Obstructive Pulmonary Disease Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Where1

Ain Shams University Hospitals
Cairo, Cairo Governorate, Egypt

Clareo Health | Nebulized Verapamil in COPD Exacerbations